Ventyx Biosciences, Inc. (VTYX) News
Filter VTYX News Items
VTYX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VTYX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest VTYX News From Around the Web
Below are the latest news stories about VENTYX BIOSCIENCES INC that investors may wish to consider to help them evaluate VTYX as an investment opportunity.
We're Keeping An Eye On Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Ventyx Biosciences Insiders Land Bargain With Gains Of US$180kInsiders who bought Ventyx Biosciences, Inc. ( NASDAQ:VTYX ) in the last 12 months may probably not pay attention to... |
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measuresKey Insights Significantly high institutional ownership implies Ventyx Biosciences' stock price is sensitive to their... |
Ventyx Biosciences Reports Q3 Financial Results and Pipeline ProgressVentyx Biosciences, Inc. ( (VTYX) ) has released its Q3 earnings. Here is a breakdown of the information Ventyx Biosciences, Inc. presented to its investors. Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focusing on the development of novel oral therapies for autoimmune and inflammatory disorders, aiming to transition treatments from injectable to oral formats. In its latest earnings report for the third quarter of 2024, Ventyx Biosciences |
Ventyx Biosciences to Participate in Three Upcoming Investor ConferencesSAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: •Event: Stifel 2024 Healthcare Conference Location: New York, NY Date: Monday, November 18, 2024 Time: 4:10-4:40 |
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate ProgressTopline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors expected to initiate by year-end, with topline results anticipated in H2 2025 Phase 2 trial of VTX2735 in patients with recurrent pericarditis expected to initiate by year-end, with topline results anticipated in H2 2025 Cash balance of $274.8M as of September 30, 2024 expected to fund operations into |
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say AnalystsIn his iconic song The Gambler, Kenny Rogers famously sang, “Every hand’s a winner, and every hand’s a loser.” This line offers valuable wisdom for investors: no matter the strategy, success in the stock market ultimately depends on how well you navigate the balance between risk and reward. Few corners of the stock market present a greater potential return for the risk than penny stocks, which trade at $5 or less. These ultra-low-priced equities offer an attractive entry point for investors look |
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024Late-breaking abstract highlights high rates of clinical and endoscopic remission among LTE completers at Week 52SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of |
VTYX Stock Rises on Strategic Equity Investment Deal With SNYVentyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232. |
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m dealUnder the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232. |